Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:50 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
NCT04849910 · Vor Biopharma · PHASE1/PHASE2 · terminated · last registry update 2025-07-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of Funding” | – | Registry record, Vor Biopharma |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD33 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-07-23Results posted on the registry: Brown University, Gemtuzumab Ozogamicin (GO) (NCT03374332)
- 2026-06-25Also stopped (terminated): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Dose Escalation -tagraxofusp-erzs + Dose Expansion at RP2D -tagraxofusp-erzs (NCT05716009)
- 2025-11-05Results posted on the registry: University of Nebraska, Cytarabine + Decitabine (NCT03226418)
- 2025-05-04Results posted on the registry: John Quigley, Gemtuzumab Ozogamicin + Venetoclax (NCT04070768)
- 2024-12-03Phase 3 first posted: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, High intensity therapies + Low intensity therapies (NCT06713837)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision